期刊文献+

肿瘤相关巨噬细胞通过FOXM1/Wnt/β-catenin通路影响乳腺癌内分泌抵抗

Tumor-associated macrophages affect breast cancer endocrine resistance through FOXM1/Wnt/β-catenin pathway
原文传递
导出
摘要 目的探讨肿瘤相关巨噬细胞(tumor associatedmacrophages,TAMs)通过叉头框M1(forkhead boxM1,FOXM1)/Wnt/β-catenin通路影响乳腺癌内分泌抵抗。方法培养他莫昔芬耐药的乳腺癌细胞,将THP-1细胞诱导成巨噬细胞(M),并进一步诱导成为肿瘤相关巨噬细胞(tumor-associated macrophages,TAMs)。MΦ在MCF-7细胞的条件培养基(conditionedmedium,CM)中培养24h后被定义为MS细胞,MΦ在MCF-7R细胞的CM中培养24h后被定义为MR细胞,MCF-7细胞在巨噬细胞的CM中培养24h后被定义为MCF-7(MΦ)细胞,MCF-7细胞在MS细胞的CM中培养24h后被定义为MCF-7(MS)细胞,MCF-7细胞在MR细胞的CM中培养24h后被定义为MCF-7(MR)细胞。借助CCK8与Transwell实验检测细胞活性与侵袭能力。qRT-PCR与Westernblot检测各组细胞中CD163、Wnt1、β-catenin、FOXM1蛋白水平。结果与MS(mRNA:1.49±0.12)(蛋白:1.15±0.12)相比,MR(mRNA:2.33±0.16)(蛋白:1.52±0.11)中CD163表达更高(t=7.28,P=0.002)(t=3.94,P=0.017),表明他莫昔芬耐药的乳腺癌细胞能诱导更多MΦ极化成TAMs。TAMs增加乳腺癌细胞中FOXM1的表达,FOXM1进一步促进Wnt/β-catenin通路激活。与MCF-7(MΦ)组细胞相比,MCF-7(MS)和MCF-7(MR)组细胞的活性与侵袭增强,MCF-7(MR)组细胞增幅最显著。较MCF-7(MΦ)组细胞,MCF-7(MS)与MCF-7(MR)组细胞中Wnt1、β-catenin、FOXM1水平显著升高,极化成最多TAMs的MCF-7(MR)组细胞中Wnt1、β-catenin、FOXM1水平最高。较MCF-7组,MCF-7(MR)组与MCF-7+pcDNA-FOXM1组中Wnt1、β-catenin水平均升高,细胞活性与侵袭能力增强,较MCF-7(MR)组,MCF-7(MR)+si-FOXM1组中Wntl、β-catenin水平降低,细胞活性与侵袭能力减弱。结论TAMs通过上调FOXM1并激活Wnt/β-catenin促进乳腺癌细胞内分泌抵抗. Objective To explore the influence of tumor-associated macrophages(TAMs)on endocrine resistance in breast cancer through the forkhead box M1(FOXM1)/Wnt/β-catenin pathway.Methods Tamoxifen-resistant breast cancer cells were cultured,THP-1 cells were induced into macrophages(MQ),and further induced into TAMs.After being cultured in the conditioned medium(CM)of MCF-7 cells for 24 hours,MQ were defined as MS cells.After being cultured in the CM of MCF-7R cells for 24 hours,MQ were defined as MR cells.MCF-7 cells,after being cultured in the CM of macrophages for 24 hours,were defined as MCF-7(MO)cells.MCF-7 cells,after being cultured in the CM of MS cells for 24 hours,were defined as MCF-7(MS)cells.MCF-7 cells,af-ter being cultured in the CM of MR cells for 24 hours,were defined as MCF-7(MR)cells.Cell viability and invasion ability were evaluated using CCK-8 and Transwell assays.The protein levels of CD163,Wntl,β-catenin,and FOXM1 in different groups were examined by qRT-PCR and Western blot.Results Compared to the MS group(mRNA:1.49±0.12,protein:1.15±0.12),CD163 expression was higher in the MR group(mRNA:2.33±0.16,protein 1.52±0.11)(t=7.28,P=0.002)(t=3.94,P=0.017),indicating that tamoxifen-resistant breast cancer cells can induce polarization of more MQ into TAMs.TAMs increased the expression of FOXM1 in breast cancer cells,which further activated the Wnt/β-catenin pathway.Compared to the MCF-7(MQ)group,the MCF-7(MS)and MCF-7(MR)groups showed enhanced cell viability and invasion,with the most significant increase observed in the MCF-7(MR)group.Compared with MCF-7(MO)cells,the levels of Wntl,β-catenin,and FOXM1 in MCF-7(MS)and MCF-7(MR)cells were significantly increased,with the highest levels observed in the MCF-7(MR)group with the most TAM polarization.Compared to the MCF-7 group,both the MCF-7(MR)and MCF-7+pcDNAFOXM1 groups showed increased levels of Wntl andβ-catenin,enhanced cell viability and invasion.Compared to the MCF-7(MR)group,the MCF-7(MR)+si-FOXM1 group showed reduced levels of Wntl andβ-catenin,weakened cell viability and invasion.Conclusion TAMs promote endocrine resistance in breast cancer by upregulating FOXM1 and activating the Wnt/β-catenin pathway.
作者 赵其龙 邵泽杰 马青山 王欣 吕昌新 Zhao Qilong;Shao Zejie;Ma Qingshan;Wang Xin;Lyu Changxin(Department of Oncology,Linyi People's Hospital,Linyi 276000,China;Department of Breast Surgery,Linyi Maternal and Child Health Hospital,Lanshan District,Linyi 276000,China;Department of Breast Surgery,Linyi People's Hospital,Linyi 276000,China)
出处 《中华内分泌外科杂志》 CAS 2023年第4期484-489,共6页 Chinese Journal of Endocrine Surgery
基金 山东省卫健委项目(2020184)。
关键词 乳腺癌 肿瘤相关巨噬细胞 叉头框M1 WNT/Β-CATENIN通路 Breast cancer Tumor-associated macrophages Forkhead box Ml Wnt/β-catenin pathway
  • 相关文献

参考文献2

二级参考文献9

  • 1朱丽喆,李雄雄,任予.托瑞米芬与他莫昔芬在乳腺癌内分泌治疗的临床进展[J].中华普通外科学文献(电子版),2017,11(3):204-207. 被引量:12
  • 2单明,康文莉,张国强.CYP2D6基因多态性对乳腺癌治疗中他莫昔芬药物疗效的影响[J].中华乳腺病杂志(电子版),2017,11(4):238-242. 被引量:5
  • 3凌琼颖,赵爱峡,谢晓楠,周文献,陆永奎,王洪学,刘燕,谭爱花,谢伟敏.长春瑞滨联合铂类治疗蒽环和紫杉类耐药的转移性乳腺癌的临床研究[J].广西医科大学学报,2017,34(12):1717-1720. 被引量:5
  • 4张振,马磊.乳腺癌患者使用他莫昔芬后脂肪肝发病特点分析[J].中国药物警戒,2018,15(9):537-540. 被引量:2
  • 5田东立,李丰鑫,邓雷,宋斐然,庞晓燕,张颐.乳腺癌患者口服他莫昔芬后子宫内膜异常的临床意义[J].中国医科大学学报,2019,48(1):62-65. 被引量:7
  • 6中国抗癌协会,国家肿瘤临床医学研究中心(天津医科大学肿瘤医院),郝希山,佟仲生,陈可欣,王瑛,刘佩芳,顾林,刘俊田,于津浦,宋丰举,黄育北,赵文华,史业辉,李慧,肖怀远.中国女性乳腺癌筛查指南[J].中国肿瘤临床,2019,46(9):429-431. 被引量:129
  • 7邹洁雅,王晓琪,孙丽飞,王文欢,王月,聂建云.乳腺癌新辅助化疗后前哨淋巴结活检术研究进展[J].中华肿瘤杂志,2019,41(8):565-568. 被引量:21
  • 8H.Agakishiev,M.M.Aggarwal,Z.Ahammed,A.V.Alakhverdyants,I.Alekseev,J.Alford,B.D.Anderson,C.D.Anson,D.Arkhipkin,G.S.Averichev,J.Balewski,D.R.Beavis,N.K.Behera,R.Bellwied,M.J.Betancourt,R.R.Betts,A.Bhasin,A.K.Bhat,H.Bichsel,J.Bieleik,J.Bielcikova,B.Biritz,L.C.Bland,W.Borowski,J.Bouchet,E.Braidot,A.V.Brandin,A.Bridgeman,S.G.Brovko,E.Bruna,S.Bueltmann,I.Bunzarov,T.P.Burton,X.Z.Cai,H.Caines,M.Calderon de la Barca Sanchez,D.Cebra,R.Cendejas,M.C.Cervantes,Z.Chajecki,P.Chaloupka,S.Chattopadhyay,H.F.Chen,J.H.Chen,J.Y.Chen,L.Chen,J.Cheng,M.Cherney,A.Chikanian,K.E.Choi,W.Christie,P.Chung,M.J.M.Codrington,R.Corliss,J.G.Cramer,H.J.Crawford,S.Dash,A.Davila Leyva,L.C.De Silvat,R.R.Debbe,T.G.Dedovich,A.A.Derevschikov,R.Derradi de Souza,L.Didenko,P.Djawotho,S.M.Dogra,X.Dong,J.L.Drachenberg,J.E.Draper,J.C.Dunlop,L.G Efimov,M.Elnim,J.Engelage,G Eppley,M.Estienne,L.Eun,O.Evdokimov,R.Fatemi,J.Fedorisin,A.Feng,R.G.Fersch,P.Filip,E.Finch,V.Fine,Y.Fisyak,C.A.Gagliardi,D.R.Gangadharan,A.Geromitsos,F.Geurts,P.Ghosh,Y.N.Gorbunov,A.Gordon,O.Grebenyuk,D.Grosnick,S.M.Guertin,A.Gupta,W.Guryn,B.Haag,O.Hajkova,A.Hamed,L-X.Han,J.W.Harris,J.P.Hays-Wehle,M.Heinz,S.Heppelmann,A.Hirsch,E.Hjort,G.W.Hoffmann,D.J.Hofiman,B.Huang,H.Z.Huang,T.J.Humanic,L.Huo,G.Igo,P.Jacobs,W.W.Jacobs,C.Jena,F.Jin,J.Joseph,E.G.Judd,S.Kabana,K.Kang,J.Kapitan,K.Kauder,H.Ke,D.Keane,A.Kechechyan,D.Kettler,D.P.Kikola,J.Kiryluk,A.Kisiel,V.Kizka,A.G.Knospe,D.D.Koetke,T.Kollegger,J.Konzer,I.Koralt,L.Koroleva,W.Korsch,L.Kotchenda,V.Kouchpil,P.Kravtsov,K.Krueger,M.Krus,L.Kumar,P.Kurnadi,M.A.C.Lamont,J.M.Landgraf,S.LaPointe,J.Lauret,A.Lebedev,R.Lednicky,J.H.Lee,W.Leight,M.J.LeVine,C.Lil,L.Li,N.Li,W.Li,X.Li,X.Li,Y.Li,Z.M.Li,M.A.Lisa,F.Liu,H.Liu,J.Liu,T.Ljubicic,W.J.Llope,R.S.Longacre,W.A.Love,Y.Lu,E.V.Lukashov,X.Luo,G.L.Ma,Y.G.Mai,D.P.Mahapatra,R.Majka,O.I.Mall,L.K.Mangotra,R.Manweiler,S.Margetis,C.Markert,H.Masui,H.S.Matis,Yu.A.Matulenko,D.MeDonald,T.S.McShane,A.Meschanin,R.Milner,N.G.Minaev,S.Mioduszewski,A.Mischke,M.K.Mitrovski,B.Mohanty,M.M.Mondal,B.Morozov,D.A.Morozov,M.G.Munhoz,M.Naglis,B.K.Nandi,T.K.Nayak,P.K.Netrakanti,L.V.Nogach,S.B.Nurushev,G.Odyniec,A.Ogawa,Oh,Ohlson,V.Okorokov,E.W.Oldag,D.Olsont,M.Pachr,B.S.Page,S.K.Pal,Y.Pandit,Y.Panebratsev,T.Pawlak,H.Pei,T.Peitzmann,C.Perkins,W.Peryt,S.C.Phatak,P.Pile,M.Planinic,M.A.Ploskon,J.Pluta,D.Plyku,N.Poljak,A.M.Poskanzer,B.V.K.S.Potukuchi,C.B.Powell,D.Prindle,N.K.Pruthi,A.M.Poskanzer,B.V.K.S.Potukuchi,B.Powell,D.Prindle,N.K.Pruthi,P.R.Pujahar,J.Putschke,H.Qiu,R.Raniwala,S.Raniwala,R.L.Ray,R.Redwine,R.Reed,H.G.Riter,J.B.Roberts,O.V.Rogachevskiy,J.L.Romero,A.Rose,L.Ruan,J.Rusnak,N.R.Sahoo,S.Sakai,I.Sakrejda,T.Sakuma,S.Salur,J.Sandweiss,E.Sangaline,A.Sarkar,J.Schambach,R.P.Scharenberg,A.M.Schmah,N.Schmitz,T.R.Schuster,J.Seele,J.Seger,I.Selyuzhenkov,P.Seyboth,E.Shahaliev,M.Shao,M.Sharma,S.S.Shi,Q.Y.Shou,E.P.Sichtermann,F.Simon,R.N.Singaraju,M.J.Skoby,N.Smirnov,H.M.Spinka,B.Srivastava,T.D.S.Stanislaus,D.Staszak,S.G.Steadman,J.R.Stevens,R.Stock,M.Strikhanov,B.Stringfellow,A.A.P.Suaide,M.C.Suarez,N.L.Subba,M.Sumbera,X.M.Sun,Y.Sun,Z.Sun,B.Surrow,D.N.Svirida,T.J.M.Symons,A.Szanto de Toledo,J.Takahashi,A.H.Tang,Z.Tang,L.H.Tarini,T.Tarnowsky,D.Thein,J.H.Thomas,J.Tian,A.R.Timmins,D.Tlusty,M.Tokarev,V.N.Tram,S.Trentalange,R.E.Tribble,Tribedy,O.D.Tsai,T.Ullrich,D.G.Underwood,G.Van Buren,G.van Nieuwenhuizen,J.A.Vanfossen,R.Varma,G.M.S.Vasconcelos,A.N.Vasiliev,F.Videbaek,Y.P.Viyogi,S.Vokal,M.Wadat,M.Walker,F.Wang,G.Wang,H.Wang,J.S.Wang,Q.Wang,X.L.Wang,Y.Wang,G.Webb,J.C.Webb,G.D.Westfall,C.Whitten,H.Wieman,S.W.Wissink,R.Witt,W.Witzke,Y.F.Wu,Xiao,W.Xie,H.Xu,N.Xu,Q.H.Xu,W.Xu,Y.Xu,Z.Xu,L.Xue,Y.Yang,P.Yepes,K.Yip,I-K.Yoo,M.Zawisza,H.Zbroszczyk,W.Zhan,J.B.Zhang,S.Zhang,W.M.Zhang,X.P.Zhang,Y.Zhang,Z.P.Zhang,J.Zhao,C.Zhong,W.Zhou,X.Zhu,Y.H.Zhu,R.Zoulkarneev,Y.Zoulkarneeva.Measurements of dihadron correlations relative to the event plane in Au+Au collisions at√^(S)NN=200 GeV[J].Chinese Physics C,2021,45(4):198-241. 被引量:351
  • 9熊发奎,崔凤,龚良庚.IVIM在乳腺癌新辅助化疗后早期反应评估的应用价值[J].中国临床医学影像杂志,2019,30(2):102-105. 被引量:4

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部